WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.
Clip from Lionsgate Television
- - - - - - - - - - - - - - - - - - - - - - - - - -
For further reading:
WeightWatchers faces an era when weight loss comes in a syringe
Behold the Ozempic effect on business
The race to develop the next generation of weight-loss drugs
- - - - - - - - - - - - - - - - - - - - - - - - - -
On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
We want to hear from you
Barclays and the legal fight over a company’s ‘controlling mind’
Shale's looming credit crunch
How Boeing plans to return the Max to the skies
Season 3 coming in 2020
The state of the Libra project
The repo market
SoftBank’s Masa Son under pressure
Corporate America's new role
Disrupting Big Ag
Luxury's resilient market
Paying for the Caesars empire
Renault, Nissan and Fiat Chrysler's quest for a deal
Warren Buffett's cash dilemma
The unicorn IPO
Encore: how €200bn of ‘dirty money’ flowed through a Danish bank
Encore: Huawei and the fight for 5G
The long courtship between Sprint and T-Mobile
Has the US bank consolidation wave begun?
Suspected £40m fraud at Patisserie Valerie
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
FT News Briefing
Money Clinic with Claer Barrett
FT World Weekly
FT News in Focus
FT Banking Weekly